Squamous Cell Cancer
Showing 1 - 25 of >10,000
Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer Trial in Boise (30% ascorbic acid in DMSO)
Recruiting
- Squamous Cell Cancer
- +3 more
- 30% ascorbic acid in DMSO
-
Boise, IdahoCenter for Biomedical Research,Inc.
Jul 2, 2023
Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)
Not yet recruiting
- Esophageal Squamous Cell Carcinomas
- +3 more
- chemotherapy combined with PD-1 inhibitors
- (no location specified)
Nov 17, 2022
Head and Neck Squamous Cell Cancer Trial in Shanghai (Toripalimab Injection, Cetuximab Solution for infusion)
Recruiting
- Head and Neck Squamous Cell Cancer
- Toripalimab Injection
- Cetuximab Solution for infusion
-
Shanghai, ChinaShanghai East Hospital
Dec 15, 2022
Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)
Recruiting
- Esophageal Squamous Cell Cancer
- Toripalimab
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023
Head and Neck Squamous Cell Cancer
Recruiting
- Head and Neck Squamous Cell Carcinoma
- OncoPrism-HNSCC™
-
San Francisco, CaliforniaCurebase
Sep 7, 2022
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Penpulimab Combined With CRT)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Penpulimab Combined With CRT
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Sep 28, 2022
Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer
Active, not recruiting
- Head and Neck Squamous Cell Cancer
- +2 more
-
Miami, Florida
- +8 more
Dec 2, 2022
Recurrent Head and Neck Squamous Cell Carcinoma Trial in Atlanta, Cleveland, Milwaukee (IMRT, Nivolumab)
Active, not recruiting
- Recurrent Head and Neck Squamous Cell Carcinoma
- IMRT
- Nivolumab
-
Atlanta, Georgia
- +3 more
Jan 10, 2023
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Head and Neck Squamous Cell Cancer Trial in London (BYL719)
Active, not recruiting
- Head and Neck Squamous Cell Cancer
-
London, Ontario, CanadaLondon Health Sciences Centre, London Regional Cancer Program
Jun 14, 2022
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma Trial in Guangzhou
Recruiting
- Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
- Tucidinostat (chidamide) and PD-1 inhibitor (Toripalimab)
-
Guangzhou, Guangdong, ChinaCancer center of Sun Yat-sen University
Jul 20, 2022
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and
Recruiting
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
- +4 more
- Cemiplimab
-
Houston, TexasM D Anderson Cancer Center
Jan 17, 2023
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma Trial in Pittsburgh (Microneedle Array Doxorubicin
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma
- Skin Cancers - Squamous Cell Carcinoma
- Microneedle Array Doxorubicin (MNA-D)
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Medical Center
Nov 28, 2022
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
Active, not recruiting
- Squamous Cell Carcinoma of the Oropharynx
- +7 more
-
Tampa, Florida
- +2 more
Dec 30, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Cleveland (Pembrolizumab, IMRT 60-66Gy)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Pembrolizumab
- IMRT 60-66Gy
-
Cleveland, Ohio
- +1 more
Jun 29, 2022
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
Stage IV Esophagus Squamous Cell Carcinoma Trial in Hangzhou (Camrelizumab, Irinotecan, Paclitaxel)
Not yet recruiting
- Stage IV Esophagus Squamous Cell Carcinoma
- Camrelizumab
- +5 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Apr 2, 2022
Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)
Completed
- Head and Neck Squamous Cell Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 24, 2022
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8
Not yet recruiting
- Oral Cavity Squamous Cell Carcinoma
- +4 more
- Near Infrared Imaging
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 5, 2022
Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)
Not yet recruiting
- Immunotherapy;Envafolimab; Esophageal Cancer
- Envafolimab
- +2 more
- (no location specified)
Apr 24, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla, San Francisco, Torrance (Pembrolizumab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
-
La Jolla, California
- +2 more
Aug 17, 2022
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +23 more
- Biospecimen Collection
- +2 more
-
Los Angeles, California
- +1 more
Jul 7, 2022
Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma Trial in Scottsdale, Tucson (Injection of TVEC into target lesions - week
Recruiting
- Squamous Cell Carcinoma
- +5 more
- Injection of TVEC into target lesions - week 1-2
- +3 more
-
Scottsdale, Arizona
- +1 more
Apr 6, 2022
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Houston (other,
Recruiting
- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Hafnium Oxide-containing Nanoparticles NBTXR3
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022